金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

已收盘 07-24 16:08:05

16.100

+0.010

+0.06%

最高16.840	最低15.830	成交量2,503万
今开16.080	昨收16.090	日振幅6.28%
总市值352.43亿	流通市值352.43亿	总股本21.89亿
成交额4.06亿	换手率1.14%	流通股本21.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":16.1,"timestamp":1784880485003,"preClose":16.09,"halted":0,"volume":25030084,"delay":0,"changeRate":0.0006215040397763558,"floatShares":2189000000,"shares":2189000000,"eps":-1.927586125771466,"marketStatus":"已收盘","change":0.01,"latestTime":"07-24 16:08:05","open":16.08,"high":16.84,"low":15.83,"amount":405541417,"amplitude":0.062772,"askPrice":16.1,"askSize":56000,"bidPrice":16.09,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-1.9279547040786722,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":16.09,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.864594,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"1153726145","title":"异动解读｜金斯瑞生物科技盘中上涨5.38%，CARVYKTI二季度销售同比增近五成叠加技术性修复延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1153726145","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153726145?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:43","pubTimestamp":1784785385,"startTime":"0","endTime":"0","summary":"7月23日，金斯瑞生物科技盘中上涨5.38%，报16.46港元/股，成交额2.22亿港元。本次上涨为公司股价自7月17日低点13.12港元以来技术性修复行情的延续。消息面上，公司联营公司传奇生物此前披露CARVYKTI二季度贸易销售净额约6.57亿美元，同比增长近五成，环比一季度5.97亿美元增长约10%。此前因环比增速放缓引发的获利回吐压力已于上周集中释放，市场重新聚焦于该产品同比高增长的趋势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜金斯瑞生物科技盘中上涨5.38%，CARVYKTI二季度销售同比增近五成叠加技术性修复延续","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653173134","title":"港股异动 |  金斯瑞生物科技(01548.HK)午后涨超13% 二季度CARVYKTI销售额达6.57亿美元 同比增长近五成","url":"https://stock-news.laohu8.com/highlight/detail?id=2653173134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653173134?lang=zh_cn&edition=full","pubTime":"2026-07-22 13:53","pubTimestamp":1784699636,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","01548","HK0000306701.USD","BK1141","HK0000320223.HKD","BK1583","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121555277","title":"异动解读｜金斯瑞生物科技盘中上涨5.12%，WAIC展示AI生物制造平台叠加股价技术性修复延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1121555277","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121555277?lang=zh_cn&edition=full","pubTime":"2026-07-22 10:43","pubTimestamp":1784688207,"startTime":"0","endTime":"0","summary":"7月22日，金斯瑞生物科技盘中上涨5.12%，报15.41港元/股，成交额2.23亿港元。此外，此前CARVYKTI二季度贸易销售净额约6.57亿美元，环比一季度5.97亿美元增长约10%，因增速放缓引发的获利回吐压力已于上周释放，公司股价自7月17日低点13.12港元持续技术性修复，本次上涨为该轮反弹行情的延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜金斯瑞生物科技盘中上涨5.12%，WAIC展示AI生物制造平台叠加股价技术性修复延续","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163042612","title":"异动解读｜金斯瑞生物科技盘中上涨5.6%，WAIC展示AI生物制造平台叠加板块反弹提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1163042612","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163042612?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:16","pubTimestamp":1784517372,"startTime":"0","endTime":"0","summary":"7月20日，金斯瑞生物科技盘中上涨5.6%，报13.96港元/股，成交额1.18亿港元。消息面上，公司近日在世界人工智能大会上重点展示了全自动黑灯实验室及与字节跳动在AI药物研发领域的深度合作，字节旗下蛋白质大模型湿实验验证命中率最高达82%，底层平台由金斯瑞TurboCHO高通量系统承接。此外，此前因CARVYKTI二季度销售增速放缓引发的获利回吐压力释放后，公司股价自7月17日低点13.12港元出现技术性修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192248107","title":"异动解读｜金斯瑞生物科技盘中下跌5.18%，CARVYKTI二季度销售增速放缓引发持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1192248107","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192248107?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:22","pubTimestamp":1784254975,"startTime":"0","endTime":"0","summary":"7月17日，金斯瑞生物科技盘中下跌5.18%，报13.68港元/股，成交额8027.44万港元。消息面上，公司联营公司传奇生物此前披露CARVYKTI®截至6月30日止季度贸易销售净额约6.57亿美元，较一季度5.97亿美元环比增长约10%，增速较一季度62%的同比增幅明显放缓。此前金斯瑞在CXO板块中报催化下7月13日及15日连续涨超5%，累计涨幅较大，销售数据公布后获利回吐压力延续至今日。同日生命科学工具和服务板块整体承压，药明康德跌5.12%、药明生物跌4.58%、英矽智能跌10.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139742382","title":"异动解读｜金斯瑞生物科技盘中下跌6.34%，CARVYKTI二季度销售环比增速放缓引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1139742382","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139742382?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:42","pubTimestamp":1784166162,"startTime":"0","endTime":"0","summary":"7月16日，金斯瑞生物科技盘中下跌6.34%，报14.19港元/股，成交额5536.45万港元。消息面上，公司于前一交易日盘后公告，联营公司传奇生物披露CARVYKTI®截至6月30日止季度贸易销售净额约6.57亿美元，较一季度的5.97亿美元环比增长约10%，增速较一季度62%的同比增幅明显放缓。此前金斯瑞生物科技在CXO板块中报业绩兑现预期推动下，7月13日及15日已连续两个交易日各涨超5%，累计涨幅较大，销售数据公布后市场出现获利回吐压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651468062","title":"金斯瑞生物科技(01548)：CARVYKTI®第二季度贸易销售净额约6.57亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651468062?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:24","pubTimestamp":1784118260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，根据传奇与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议，CARVYKTI®于截至2026年6月30日止季度产生贸易销售净额约6.57亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技(01548)：CARVYKTI®第二季度贸易销售净额约6.57亿美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","HK0000320264.USD","BK1576","BK1141","BK1583","01548","HK0000306701.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111231414","title":"金斯瑞生物科技（01548）：传奇生物披露CARVYKTI® 2026年二季度净销售额约6.57亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111231414","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111231414?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:21","pubTimestamp":1784118087,"startTime":"0","endTime":"0","summary":"2026年7月15日，金斯瑞生物科技股份有限公司发布自愿性公告称，其联营公司传奇生物科技股份有限公司已向美国证券交易委员会提交6-K表格，并公布CARVYKTI在截至2026年6月30日止季度的初步销售数据。根据传奇生物与Janssen Biotech, Inc. 于2017年12月21日签订的合作及许可协议，CARVYKTI在该季度产生的贸易销售净额约为6.57亿美元。公告指出，上述销售数据由合作伙伴Janssen Biotech, Inc. 提供，传奇生物及金斯瑞生物科技均未对该数字的准确性进行独立核实。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102859451","title":"异动解读｜金斯瑞生物科技盘中上涨5.04%，CXO龙头中报业绩超预期带动板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1102859451","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102859451?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:21","pubTimestamp":1784085695,"startTime":"0","endTime":"0","summary":"7月15日，金斯瑞生物科技盘中上涨5.04%，报15.0港元/股，成交额2.06亿港元。CXO板块中报业绩兑现窗口持续开启，多家券商指出前期低价订单逐步消化后，行业收入与利润双拐点确立，板块估值修复逻辑进一步强化。金斯瑞生物科技作为全球基因合成龙头及生物制剂CRDMO核心平台，受益于行业景气度回暖及AI制药需求扩张。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163068883","title":"异动解读｜金斯瑞生物科技盘中上涨5.27%，CXO板块中报业绩兑现窗口持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1163068883","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163068883?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:38","pubTimestamp":1783906730,"startTime":"0","endTime":"0","summary":"7月13日，金斯瑞生物科技盘中上涨5.27%，报14.65港元/股，成交额7857.66万港元。消息面上，CXO板块中报业绩兑现窗口开启，多家券商指出行业新签订单增速大幅提升，前期低价订单逐步消化后，板块收入与利润双拐点确立。此前数据显示，22家CXO上市公司一季度收入、归母净利润总额增速分别同比增长18.6%和21.9%，国内CXO公司订单充足、量价双升，报表端大幅改善预期正在逐步兑现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135826529","title":"异动解读｜金斯瑞生物科技盘中上涨5.38%，CXO板块中报业绩窗口开启叠加政策催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1135826529","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135826529?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:23","pubTimestamp":1783650215,"startTime":"0","endTime":"0","summary":"7月10日，金斯瑞生物科技盘中上涨5.38%，报13.91港元/股，成交额5668.11万港元。消息面上，CXO板块中报业绩兑现窗口开启，创新药产业链盈利逻辑开始在报表端兑现。多家券商指出CXO行业新签订单增速大幅提升，前期低价订单逐步消化后，板块收入与利润双拐点确立。金斯瑞生物科技是一家主要从事生命科学研究产品及服务的投资控股公司，业务覆盖基因合成、生物制剂开发、工业合成生物及细胞疗法等领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108383272","title":"异动解读｜金斯瑞生物科技盘中上涨5.07%，AI制药主题催化叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1108383272","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108383272?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:10","pubTimestamp":1783303823,"startTime":"0","endTime":"0","summary":"7月6日，金斯瑞生物科技盘中上涨5.07%，报14.44港元/股，成交额1.13亿港元。消息面上，近日市场对AI制药方向关注度持续升温，金斯瑞作为基因合成及生命科学工具平台型企业，被视为AI制药产业链的底层基础设施服务商，受到资金追捧。此前有消息指字节跳动AI制药主体AnewTherapeutics已在新加坡注册，进一步提振市场对AI制药湿实验需求爆发的预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109972413","title":"金斯瑞生物科技6月股份变动月报：新增发行130,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1109972413","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109972413?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:15","pubTimestamp":1782983735,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技于2026年7月2日发布6月股份变动月报，报告期为截至2026年6月30日止月份。公告显示，截至报告期末，公司注册股本维持5,000,000,000股，每股面值0.001美元，注册股本总额5,000,000美元，未出现增减变动。报告期内，金斯瑞生物科技已发行股份由上月底的2,188,417,343股增至2,188,547,343股，新增130,000股，主要源自“首次公开发售后股份期权计划”中股份期权行使所致。截至2026年6月30日，金斯瑞生物科技已发行股份总数为2,188,547,343股。本次公告由董事孟建革签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137115406","title":"异动解读｜金斯瑞生物科技盘中上涨6.46%，报13.02港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137115406","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137115406?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:31","pubTimestamp":1782959490,"startTime":"0","endTime":"0","summary":"7月2日，金斯瑞生物科技盘中上涨6.46%，报13.02港元/股，成交额2.18亿港元。金斯瑞生物科技所在的生命科学工具和服务行业中，个股整体表现偏强，其中药明生物涨3.35%，药明合联涨2.80%，英矽智能涨1.77%，晶泰控股涨1.57%，药明康德跌0.72%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647034208","title":"医药外包概念走强 昭衍新药(06127)涨9.16% 机构指相关标的业绩有望超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2647034208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647034208?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:20","pubTimestamp":1782699626,"startTime":"0","endTime":"0","summary":"消息面上，东吴证券研究指，22家CXO上市公司2026Q1实现收入、归母净利润、扣非归母净利润总额增速分别同比增长18.6%、21.9%、63.5%，业绩逐季度改善。根据医药魔方，2026Q1，国内创新药一级市场融资总金额25.9亿美元，同比上涨128.6%，2026Q1中国相关交易数量及金额涨势迅猛，总金额达614亿美元，大幅领先国外交易总金额。该机构认为，随着中国创新药在全球研发创新中的比重提升，与其配套的CXO产业链将进一步增强。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984678","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","BK1576","HK0000320264.USD","LU2125910500.SGD","HK0000306685.HKD","BK1141","LU0708995583.HKD","LU0326950275.SGD","HK0000320223.HKD","LU0348766576.USD","603127","06127","LU0417516902.SGD","LU1794554557.SGD","LU0823426308.USD","03347","LU0348767384.USD","LU0979878070.USD","LU1880383366.USD","LU0052750758.USD","02359","LU0140636845.USD","02269","LU1720050803.USD","LU1242518931.SGD","BK1574","01548","LU0516422952.EUR","LU3063872942.SGD","LU0043850808.USD","BK1583","LU1688375341.USD","HK0000306701.USD","BK0216","BK1191","LU0588546209.SGD","LU0320764599.SGD","159938","LU0181495838.USD","09939","LU0456846285.SGD","LU0348825331.USD","LU0417516738.SGD","LU1046422090.SGD","BK1161","06821","03759","LU2045819591.USD","LU2242644610.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645866019","title":"CXO概念走强 凯莱英 (06821) 涨 17.77% BIO2026大会看好中国CXO高效率优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645866019?lang=zh_cn&edition=full","pubTime":"2026-06-24 11:17","pubTimestamp":1782271026,"startTime":"0","endTime":"0","summary":"全球生物技术领域盛会BIO2026大会于6月22日至25日在美国圣地亚哥召开，汇聚全球超20000名行业参与者，覆盖人工智能与数字健康、细胞与基因治疗等前沿领域，中国CXO企业的高效率优势备受关注。光大证券研报指，2026年6月22日至25日BIO2026大会举办，70余个国家超2万名业内人士参会，覆盖18大生物医药核心议题，凯莱英、泰格医药、博腾股份等国内CXO企业参展，英硅智能同期落地AI药物研发海外合作。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","LU1046422090.SGD","LU0348735423.USD","03347","HK0000306701.USD","02359","LU0348766576.USD","LU1242518931.SGD","LU0456827905.SGD","LU0708995583.HKD","LU0043850808.USD","LU1794554557.SGD","02269","01548","HK0000306685.HKD","LU0516422952.EUR","LU1720050803.USD","002821","HK0000320264.USD","LU0326950275.SGD","LU0359201612.USD","03759","BK1583","LU0052750758.USD","BK0239","LU0359202008.SGD","LU0456846285.SGD","LU1880383366.USD","LU2039709279.SGD","SG9999002463.SGD","HK0000320223.HKD","LU0051755006.USD","LU0856984785.SGD","LU0572944931.SGD","LU0588546209.SGD","06127","BK0132","BK1521","LU2242644610.SGD","LU0140636845.USD","LU0320764599.SGD","LU3063872942.SGD","BK1576","LU0327786744.USD","LU0516422366.SGD","LU0819121731.USD","LU0039217434.USD","BK1141","06821","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645865054","title":"CRO概念股早盘表现强势 凯莱英涨超14%金斯瑞生物科技涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645865054","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645865054?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:35","pubTimestamp":1782268500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　CRO概念股早盘表现强势，截至发稿，凯莱英（06821）上涨14.05%，报110.40港元；金斯瑞生物科技（01548）上涨8.56%，报11.80港元；药明康德（02359）上涨8.56%，报142港元；泰格医药（03347）上涨5.67%，报32.74港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-24/doc-inienpmx8299253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","06821","HK0000306701.USD","BK1583","HK0000320223.HKD","01548","BK1576","BK0239","BK1191","BK1141","LU1328615791.USD","BK0132","002821","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645653708","title":"港股异动 | CRO概念股表现强势 BIO大会凸显中国CXO全球竞争力 医药领域开放迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2645653708","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645653708?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:00","pubTimestamp":1782266401,"startTime":"0","endTime":"0","summary":"消息面上，BIO 2026国际生物科技大会于6月22日至25日在美国圣地亚哥召开，中国CXO企业的高效率优势得到全球认可，海外订单拓展空间进一步打开。东方证券发布研报称，从CXO景气度关键指标的最新数据来看：2026年前五个月，国内资金端、研发端、订单端多重因素共振向上，国内CXO行业高景气持续。该行认为，国内CXO公司订单充足、量价双升，随着订单执行转化，将会带来报表端大幅改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0708995583.HKD","LU1046422090.SGD","01548","BK4588","LU0052750758.USD","03347","BK1515","CXO","BK1191","LU1169589451.USD","BK4585","VXUS","02359","LU2045819591.USD","HK0000320264.USD","HK0000306701.USD","LU2125910500.SGD","159938","06821","BK4121","LU0348766576.USD","BK1574","LU1169590202.USD","BK1576","HK0000320223.HKD","LU2242644610.SGD","09939","BK1583","BIO","LU0320764599.SGD","HK0000306685.HKD","BK1141","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114917963","title":"异动解读｜金斯瑞生物科技盘中上涨5.34%，此前因传奇生物美股大跌回调后呈修复走势","url":"https://stock-news.laohu8.com/highlight/detail?id=1114917963","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114917963?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:41","pubTimestamp":1782265310,"startTime":"0","endTime":"0","summary":"6月24日，金斯瑞生物科技盘中上涨5.34%，报11.58港元，成交额3764.29万港元。消息面上，公司股价此前于6月22日因联营公司传奇生物美股大幅下跌而回调逾8%至10.76港元附近，当前呈现技术性修复走势。同日生命科学板块整体回暖，药明康德涨3.75%、药明生物涨2.63%、药明合联涨5.3%，板块情绪改善对股价形成支撑。金斯瑞生物科技是一家主要从事生命科学研究产品及服务的投资控股公司，旗下细胞疗法分部通过联营公司传奇生物开发CAR-T疗法，主要在中国及海外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167041365","title":"异动解读｜金斯瑞生物科技盘中下跌8.14%，联营公司传奇生物美股大跌拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1167041365","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167041365?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:13","pubTimestamp":1782094439,"startTime":"0","endTime":"0","summary":"6月22日，金斯瑞生物科技盘中下跌8.14%，报10.76港元，成交额1.03亿港元。消息面上，公司联营公司传奇生物上周五在美股大幅下跌，市场情绪传导至港股母公司。同日生命科学板块整体走弱，药明生物跌3.18%、晶泰控股跌3.93%、英矽智能跌2.66%，行业情绪低迷进一步加剧抛压。金斯瑞生物科技是一家主要从事生命科学研究产品及服务的投资控股公司，旗下细胞疗法分部通过联营公司传奇生物开发CAR-T疗法，主要在中国及海外市场开展业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.1104},{"period":"1month","weight":0.4802},{"period":"3month","weight":0.1617},{"period":"6month","weight":0.2098},{"period":"1year","weight":-0.114},{"period":"ytd","weight":0.2955}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057883},{"month":5,"riseRate":0.454545,"avgChangeRate":0.061694},{"month":6,"riseRate":0.545455,"avgChangeRate":0.030877},{"month":7,"riseRate":0.636364,"avgChangeRate":0.097617},{"month":8,"riseRate":0.4,"avgChangeRate":0.101263},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}